tirzepatide for alzheimer's patients Diabetes Dialogue: Semaglutide Falls Short Alzheimer Disease, Shows Promise in T1D A novel therapeutic prospect: a
Description
Sherly Soleiman, MD discusses individual risk with each patient at consultation.
Tirzepatide (Mounjaro, Zepbound) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (Mounjaro) and chronic weight management (Zepbound)
The goal is always the same: support meaningful weight loss in a way that respects your long-term safety
Tirzepatide is already doing the heavy metabolic lifting
When combined with medical guidance and long-term lifestyle changes, Tirzepatide treatment offers a realistic and effective path toward improved wellness, greater confidence, and lasting results.
